Regulus Therapeutics (RGLS) Tops Q4 EPS by 11c

Regulus Therapeutics (NASDAQ: RGLS) reported Q4 EPS of ($0.14), $0.11 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $10.9 million versus the consensus estimate of $5.09 million.

For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.

You May Also Be Interested In

• SpaceX sets date for maiden earnings report: Why August 4 is make-or-break
• First United (FUNC) Tops Q2 EPS by 8c
• Calix, Inc. (CALX) Tops Q2 EPS by 6c, Offers Guidance